EIF2AK3 and amyotrophic lateral sclerosis: The aim of the current study was to reconcile the inconsistent outcomes of promising PERK modulators, namely GSK2606414, salubrinal, and Sephin1, by conducting side-by-side testing in ALS-relevant assay systems, and ultimately determining whether PERK is a promising pharmacological target for ALS.